國立虎尾科技大學 |

Biomarkers in Cancer Therapy = Liquid Biopsy Comes of Age /

Record Type:	Language materials, printed : Monograph/item
Title/Author:	Biomarkers in Cancer Therapy/ edited by Hideaki Shimada.
Reminder of title:	Liquid Biopsy Comes of Age /
other author:	Shimada, Hideaki.
Description:	VIII, 157 p. 22 illus., 17 illus. in color.online resource. :
Contained By:	Springer Nature eBook
Subject:	Oncology . -
Online resource:	https://doi.org/10.1007/978-981-13-7295-7
ISBN:	9789811372957

Biomarkers in Cancer Therapy = Liquid Biopsy Comes of Age /
Biomarkers in Cancer TherapyLiquid Biopsy Comes of Age /[electronic resource] :edited by Hideaki Shimada. - 1st ed. 2019. - VIII, 157 p. 22 illus., 17 illus. in color.online resource.

I. General Statement -- 1.Exosomes -- 2.Cell Free DNA -- 3.Autoantibody -- 4.Serum Protein -- Part II. Application to Each Cancer -- 5.Head and Neck Cancer / Esophageal Cancer -- 6.Gastric Cancer -- 7.Colorectal Cancer -- 8.Liver Cancer -- 9.Pancreas Cancer -- 10.Lung Cancer -- 11.Breast Cancer -- 12.Prostate Cancer -- 13.Gynecological Cancers -- 14.Malignant Pleural Mesothelioma.

This book sheds new light on research into liquid biopsy biomarkers for cancer screening. The chapters in the first half address exosomes, circulating cell-free DNA and autoantibodies, and main solid cancers, along with companion biomarkers – all of which serve as the basis for exploring key research questions for future clinical trials in the book’s second half. The study of biomarkers has evolved rapidly thanks to advances in precision medicine. While conventional cancer biomarker research is focused on proteomics or gene analysis of resected tissue, diagnostic markers have since become significant in terms of gauging the effectiveness of molecularly targeted drugs or the likelihood of a favorable prognosis. In addition, conventional treatment strategy, which draws on archives of resected tissue samples, is now gradually being replaced by monitoring with the use of liquid biopsy, which is poised to become the new mainstream in molecular targeting therapy. The contributing authors discuss in detail biomarkers, molecular targets for treatment, monitoring markers to evaluate treatment responses, prognostic markers, and screening and early diagnosis. Accordingly, this excellent collection of texts will benefit not only oncologists, but also medical and biological researchers and pharmaceutical scientists involved in the latest cancer research.

ISBN: 9789811372957

Standard No.: 10.1007/978-981-13-7295-7doiSubjects--Topical Terms:

1253469
Oncology .

LC Class. No.: RC254-282

Dewey Class. No.: 616.994

Biomarkers in Cancer Therapy = Liquid Biopsy Comes of Age /
LDR:03082nam a22003975i 4500 001 1005300
003 DE-He213
005 20200706004931.0
007 cr nn 008mamaa
008 210106s2019 si | s |||| 0|eng d
020 $a 9789811372957 $9 978-981-13-7295-7
024 7 $a 10.1007/978-981-13-7295-7 $2 doi
035 $a 978-981-13-7295-7
050 4 $a RC254-282
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
072 7 $a MJCL $2 thema
082 0 4 $a 616.994 $2 23
245 1 0 $a Biomarkers in Cancer Therapy $h [electronic resource] : $b Liquid Biopsy Comes of Age / $c edited by Hideaki Shimada.
250 $a 1st ed. 2019.
264 1 $a Singapore : $b Springer Singapore : $b Imprint: Springer, $c 2019.
300 $a VIII, 157 p. 22 illus., 17 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
505 0 $a I. General Statement -- 1.Exosomes -- 2.Cell Free DNA -- 3.Autoantibody -- 4.Serum Protein -- Part II. Application to Each Cancer -- 5.Head and Neck Cancer / Esophageal Cancer -- 6.Gastric Cancer -- 7.Colorectal Cancer -- 8.Liver Cancer -- 9.Pancreas Cancer -- 10.Lung Cancer -- 11.Breast Cancer -- 12.Prostate Cancer -- 13.Gynecological Cancers -- 14.Malignant Pleural Mesothelioma.
520 $a This book sheds new light on research into liquid biopsy biomarkers for cancer screening. The chapters in the first half address exosomes, circulating cell-free DNA and autoantibodies, and main solid cancers, along with companion biomarkers – all of which serve as the basis for exploring key research questions for future clinical trials in the book’s second half. The study of biomarkers has evolved rapidly thanks to advances in precision medicine. While conventional cancer biomarker research is focused on proteomics or gene analysis of resected tissue, diagnostic markers have since become significant in terms of gauging the effectiveness of molecularly targeted drugs or the likelihood of a favorable prognosis. In addition, conventional treatment strategy, which draws on archives of resected tissue samples, is now gradually being replaced by monitoring with the use of liquid biopsy, which is poised to become the new mainstream in molecular targeting therapy. The contributing authors discuss in detail biomarkers, molecular targets for treatment, monitoring markers to evaluate treatment responses, prognostic markers, and screening and early diagnosis. Accordingly, this excellent collection of texts will benefit not only oncologists, but also medical and biological researchers and pharmaceutical scientists involved in the latest cancer research.
650 0 $a Oncology . $3 1253469
650 0 $a Cancer research. $3 1253664
650 1 4 $a Oncology. $3 593951
650 2 4 $a Cancer Research. $3 668358
700 1 $a Shimada, Hideaki. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1227508
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9789811372940
776 0 8 $i Printed edition: $z 9789811372964
776 0 8 $i Printed edition: $z 9789811372971
856 4 0 $u https://doi.org/10.1007/978-981-13-7295-7
912 $a ZDB-2-SME
912 $a ZDB-2-SXM
950 $a Medicine (SpringerNature-11650)
950 $a Medicine (R0) (SpringerNature-43714)